TCT 2024 - TCTMD.com
Oct 27, 2024 · TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help …
TCTMD - tctmd.com
TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.
What’s Going to Be Big at TCT 2024? | tctmd.com
Oct 17, 2024 · TCT 2024, the annual scientific showcase of interventional cardiovascular medicine, is returning once again to Washington, DC. The 4-day meeting starts Sunday, …
Amit Goyal, MD | tctmd.com
6 days ago · Amit Goyal, MD, is a structural interventional cardiologist and Director of the CICU at the Dallas VA Medical Center, Editor-in-Chief of US Cardiology Review, and co-founder —with …
Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 …
Dec 4, 2024 · In a head-to-head tussle between two obesity drugs, tirzepatide came out on top of semaglutide for weight loss, according to topline results from the SURMOUNT-5 trial released …
Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial …
Oct 29, 2024 · WASHINGTON, DC—The routine use of colchicine, an anti-inflammatory agent with a challenging side-effect profile, fails to reduce the risk of major adverse cardiovascular …
AHA 2024 | tctmd.com
TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save …
ECLIPSE: Orbital Atherectomy No Better Than Balloon Angioplasty …
Oct 29, 2024 · Interventional cardiologists have many tools at their fingertips to address calcified lesions—which are known to be among the most complex—including angioplasty with …
Slides | tctmd.com
Apr 14, 2024 · TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help …
ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients
Oct 30, 2024 · WASHINGTON, DC—The ACURATE investigational device exemption (IDE) trial has provided disappointing results, with the Acurate neo2 TAVI valve (Boston Scientific) falling …